Showing results (381-390 of 514) with videos related to

Sort By:
Pageof 52
Chemistry (Weinheim an Der Bergstrasse, Germany)|September 28, 2019
The First Anticancer Tris(pyrazolyl)borate Molybdenum(IV) Complexes: Tested in Vitro and in Vivo-A Comparison of O,O-, S,O-, and N,N-Chelate EffectsIker Berasaluce, Klaudia Cseh, Alexander Roller, et al.
Dalton Transactions (Cambridge, England : 2003)|February 17, 2017
{Ru(CO)<sub>x</sub>}-Core complexes with benzimidazole ligands: synthesis, X-ray structure and evaluation of anticancer activity in vivoGabriella Tamasi, Antonello Merlino, Federica Scaletti, et al.
Dalton Transactions (Cambridge, England : 2003)|July 2, 2026
Novel ruthenium(II) complexes bearing polypyridyl and 1,2,4-oxadiazole ligands: from synthesis to <i>in vitro</i> and <i>in vivo</i> anticancer evaluationLaura Marretta, Daniel Valcanover, Maria Pia Buono, et al.
Angewandte Chemie (International Ed. in English)|April 22, 2016
Photoreduction of Terrigenous Fe-Humic Substances Leads to Bioavailable Iron in OceansAmir Blazevic, Ewelina Orlowska, Wolfgang Kandioller, et al.
Bioconjugate Chemistry|August 11, 2017
Multifunctional α<sub>v</sub>β<sub>6</sub> Integrin-Specific Peptide-Pt(IV) Conjugates for Cancer Cell TargetingAnne C Conibear, Sonja Hager, Josef Mayr, et al.
Journal of Medicinal Chemistry|December 1, 2012
Unsymmetric mono- and dinuclear platinum(IV) complexes featuring an ethylene glycol moiety: synthesis, characterization, and biological activityVerena Pichler, Petra Heffeter, Seied M Valiahdi, et al.
Metallomics : Integrated Biometal Science|April 4, 2019
First-in-class ruthenium anticancer drug (KP1339/IT-139) induces an immunogenic cell death signature in colorectal spheroids in vitroDebora Wernitznig, Konstantinos Kiakos, Giorgia Del Favero, et al.
Current Research in Food Science|December 20, 2024
Pulsed electric field processing of edible insect slurries induces thermally-assisted microbial inactivationL J H Sweers, M Mishyna, L M Ahrné, et al.
Chemical Science|May 17, 2017
An albumin-based tumor-targeted oxaliplatin prodrug with distinctly improved anticancer activity <i>in vivo</i>Josef Mayr, Petra Heffeter, Diana Groza, et al.
Pageof 52